Results from this open-label study show that subcutaneously administered epoetin delta, the only human-cell-derived epoetin, was effective for the control of anaemia in this group of CKD patients (predialysis, peritoneal dialysis and haemodialysis) over 52 weeks. The gene discussed is EPO; the disease is anemia (phenotype).